Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers.

IF 5.5 3区 医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-07-08 DOI:10.1080/14760584.2024.2374287
Anastasia Demidova, Laëtitia Douguet, Ingrid Fert, Yu Wei, Pierre Charneau, Laleh Majlessi
{"title":"Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers.","authors":"Anastasia Demidova, Laëtitia Douguet, Ingrid Fert, Yu Wei, Pierre Charneau, Laleh Majlessi","doi":"10.1080/14760584.2024.2374287","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Persistent infections with the human papilloma viruses, HPV16 and HPV18, are associated with multiple cancers. Although prophylactic vaccines that induce HPV-neutralizing antibodies are effective against primary infections, they have no effect on HPV-mediated malignancies against which there is no approved immuno-therapy. Active research is ongoing on immunotherapy of these cancers.</p><p><strong>Areas covered: </strong>In this review, we compared the preclinical efficacy of vaccine platforms used to treat HPV-induced tumors in the standard model of mice grafted with TC-1 cells, which express the HPV16 E6 and E7 oncoproteins. We searched for the key words, 'HPV,' 'vaccine,' 'therapy,' 'E7,' 'tumor,' 'T cells' and 'mice' for the period from 2005 to 2023 in PubMed and found 330 publications. Among them, we selected the most relevant to extract preclinical antitumor results to enable cross-sectional comparison of their efficacy.</p><p><strong>Expert opinion section: </strong>We compared these studies for HPV antigen design, immunization regimen, immunogenicity, and antitumor effect, considering their drawbacks and advantages. Among all strategies used in murine models, certain adjuvanted proteins and viral vectors showed the strongest antitumor effects, with the use of lentiviral vectors being the only approach to result in complete tumor eradication in 100% of experimental individuals while providing the longest-lasting memory.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2374287","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Persistent infections with the human papilloma viruses, HPV16 and HPV18, are associated with multiple cancers. Although prophylactic vaccines that induce HPV-neutralizing antibodies are effective against primary infections, they have no effect on HPV-mediated malignancies against which there is no approved immuno-therapy. Active research is ongoing on immunotherapy of these cancers.

Areas covered: In this review, we compared the preclinical efficacy of vaccine platforms used to treat HPV-induced tumors in the standard model of mice grafted with TC-1 cells, which express the HPV16 E6 and E7 oncoproteins. We searched for the key words, 'HPV,' 'vaccine,' 'therapy,' 'E7,' 'tumor,' 'T cells' and 'mice' for the period from 2005 to 2023 in PubMed and found 330 publications. Among them, we selected the most relevant to extract preclinical antitumor results to enable cross-sectional comparison of their efficacy.

Expert opinion section: We compared these studies for HPV antigen design, immunization regimen, immunogenicity, and antitumor effect, considering their drawbacks and advantages. Among all strategies used in murine models, certain adjuvanted proteins and viral vectors showed the strongest antitumor effects, with the use of lentiviral vectors being the only approach to result in complete tumor eradication in 100% of experimental individuals while providing the longest-lasting memory.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对人乳头瘤病毒诱发癌症的免疫疗法临床前疗效比较。
导言:人类乳头瘤病毒 HPV16 和 HPV18 的持续感染与多种癌症有关。虽然诱导人乳头状瘤病毒中和抗体的预防性疫苗对原发性感染有效,但对人乳头状瘤病毒介导的恶性肿瘤却没有效果,目前还没有针对这些肿瘤的免疫疗法获得批准。目前,针对这些癌症的免疫疗法研究正在进行中:在这篇综述中,我们比较了用于治疗HPV诱导的肿瘤的疫苗平台的临床前疗效,这些疫苗平台在小鼠标准模型中接种了表达HPV16 E6和E7肿瘤蛋白的TC-1细胞。我们在 PubMed 上搜索了 2005 年至 2023 年期间的关键词 "HPV"、"疫苗"、"治疗"、"E7"、"肿瘤"、"T 细胞 "和 "小鼠",共找到 330 篇论文。在这些研究中,我们选择了与临床前抗肿瘤结果最相关的研究,以便对其疗效进行横向比较:我们对这些研究的 HPV 抗原设计、免疫方案、免疫原性和抗肿瘤效果进行了比较,同时考虑了它们的缺点和优点。在小鼠模型中使用的所有策略中,某些佐剂蛋白和病毒载体显示出最强的抗肿瘤效果,而使用慢病毒载体是唯一能使100%的实验个体完全根除肿瘤,同时提供最持久记忆的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Vaccines
Expert Review of Vaccines 医学-免疫学
CiteScore
9.10
自引率
3.20%
发文量
136
审稿时长
4-8 weeks
期刊介绍: Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
期刊最新文献
Hookworm vaccines: current and future directions. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines. Estimating the time required to reach HPV vaccination targets across Europe. Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024. Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1